This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Immunogen
This Kallikrein 2 (KLK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 166-197 amino acids from the C-terminal region of human Kallikrein 2 (KLK2).
KLK2
Reaktivität: Human
WB, IP
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
For WB starting dilution is: 1:1000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
2 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
Kallikrein 2 (KLK2)
Andere Bezeichnung
Kallikrein 2
Hintergrund
Kallikreins are a group of serine proteases manifesting diverse physiological functions. The glandular kallikreins are a distinct group of serine proteases with an ability to release vasoactive peptides from kininogen in vitro, although the kininogenase activity of different kallikreins is highly variable. Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin. Many kallikrein genes are differentially expressed in various malignancies. Human glandular kallikrein (hK2, encoded by the KLK2 gene) is an emerging tumor marker for prostate cancer.